<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00454272</url>
  </required_header>
  <id_info>
    <org_study_id>M000507_6004</org_study_id>
    <nct_id>NCT00454272</nct_id>
  </id_info>
  <brief_title>Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients</brief_title>
  <official_title>Comparison of Teicoplanin and Vancomycin in Initial Empirical Antibiotic Regimen for Febrile Neutropenic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to evaluate the efficacy and safety of Teicoplanin versus Vancomycin&#xD;
      as part of the initial antibiotic regimen in the therapy of patients with fever and&#xD;
      neutropenia .&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy parameter will be the Response</measure>
    <time_frame>4 to 6 days after study drug discontinuation.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety will be assessed for all randomized patients who received at least one dose</measure>
    <time_frame>1 month after the last dose of the drug</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">197</enrollment>
  <condition>Infection</condition>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>1, Vancomycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2, Teicoplanin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Teicoplanin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teicoplanin</intervention_name>
    <arm_group_label>2, Teicoplanin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <arm_group_label>1, Vancomycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Will initiate study drug treatment in the hospital;&#xD;
&#xD;
          -  Has a life expectancy exc. 1 month.Is male or a non-pregnant, non-lactating female,&#xD;
             who is post-menopausal, surgically sterilized; or has been using one or more birth&#xD;
             control methods for at least two months prior to study entry.&#xD;
&#xD;
          -  Effective contraception must continue for at least 30 days after treatment&#xD;
             discontinuation;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has a history of suspected or documented Type I hypersensitivity reaction (e.g.&#xD;
             anaphylactic or anaphylactoid shock, respiratory distress from bronchospasm or rash)&#xD;
             to glycopeptides (vancomycin or teicoplanin), aminoglycosides, b-lactams or&#xD;
             cephalosporins&#xD;
&#xD;
          -  Has renal dysfunction requiring dialysis ;&#xD;
&#xD;
          -  Has neutropenia associated with a syndrome that is not generally thought to be&#xD;
             associated with a high risk of bacterial infection (e.g., chronic benign neutropenia);&#xD;
&#xD;
          -  Is in blast crisis of chronic myeloid leukemia;&#xD;
&#xD;
          -  Has a known underlying immunocompromising disease likely to interfere with the&#xD;
             evaluation of therapeutic response, such as infection with human immunodeficiency&#xD;
             virus (HIV) ;&#xD;
&#xD;
          -  Had isolation and identification of a specific pathogen suspected to be responsible&#xD;
             for fever ;Has documented colonization with vancomycin-resistant Enterococcus faecium&#xD;
             or with Enterococcus faecalis&#xD;
&#xD;
          -  Had received more than one dose of a systemic (whether oral or parenteral) antibiotic&#xD;
             within 3 calendar days preceding the initial therapy for this episode of fever;&#xD;
&#xD;
          -  Has received oral vancomycin for prophylaxis of Gram-positive infection;&#xD;
&#xD;
          -  Requires addition of anti-viral, anti-anaerobic or anti-fungal coverage at the same&#xD;
             time as study medication; however, antiviral or antifungal prophylaxis is allowed,&#xD;
             provided that it is not started at the same time than study medication.&#xD;
&#xD;
          -  Has suspected, invasive fungal disease (e.g. image of necrotic pneumonia), peri-rectal&#xD;
             infection, liver abscess, or necrotizing enterocolitis (typhlitis).&#xD;
&#xD;
          -  Had a negative serum or urine laboratory pregnancy test (for all women except those&#xD;
             post-menopausal or surgically sterilized).&#xD;
&#xD;
          -  The patient has one of the following:Leukemia, lymphoma, Hodgkin's disease, solid&#xD;
             tumors or who had undergone bone marrow transplantation (for any reason)&#xD;
&#xD;
          -  Had neutropenia at the time of initiation of initial empiric antibiotic therapy,&#xD;
             defined as &lt;500 neutrophils/mm3 of blood; or if Â³500 but &lt;1,000 neutrophils/mm3 and&#xD;
             expected to fall below 500 neutrophils/mm3 within 48 hours.&#xD;
&#xD;
          -  Has at least one of the following conditions:&#xD;
&#xD;
          -  clinically obvious, serious catheter-related infections. For a patient with documented&#xD;
             catheter-related infection due to an organism other than coagulase negative&#xD;
             staphylococci, the catheter has been removed within 24 hours of identification&#xD;
             (removal over a guidewire is permitted).&#xD;
&#xD;
          -  Intensive chemotherapy that produces substantial mucosal damage (i.e., high-dose&#xD;
             cytarabine (&gt; 1 g/m2/day, which increases the risk for penicillin resistant&#xD;
             streptococcal infections, particularly those due to viridans streptococci);&#xD;
&#xD;
          -  prophylaxis with quinolones before the onset of the febrile episode; known&#xD;
             colonization with pneumococci that are resistant to penicillin and -cephalosporins or&#xD;
             methicillin-resistant S. aureus; a blood culture positive for gram-positive bacteria&#xD;
             before final identification and susceptibility&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edibe Taylan</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi aventis administrative office</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 29, 2007</study_first_submitted>
  <study_first_submitted_qc>March 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2007</study_first_posted>
  <last_update_submitted>March 5, 2009</last_update_submitted>
  <last_update_submitted_qc>March 5, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>febrile</keyword>
  <keyword>neutropenia</keyword>
  <keyword>cancer</keyword>
  <keyword>Gram positive infection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Teicoplanin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

